Nature Communications (Dec 2019)
IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis
- Christina Lückel,
- Felix Picard,
- Hartmann Raifer,
- Lucia Campos Carrascosa,
- Anna Guralnik,
- Yajuan Zhang,
- Matthias Klein,
- Stefan Bittner,
- Falk Steffen,
- Sonja Moos,
- Federico Marini,
- Renee Gloury,
- Florian C. Kurschus,
- Ying-Yin Chao,
- Wilhelm Bertrams,
- Veronika Sexl,
- Bernd Schmeck,
- Lynn Bonetti,
- Melanie Grusdat,
- Michael Lohoff,
- Christina E. Zielinski,
- Frauke Zipp,
- Axel Kallies,
- Dirk Brenner,
- Michael Berger,
- Tobias Bopp,
- Björn Tackenberg,
- Magdalena Huber
Affiliations
- Christina Lückel
- Institute for Medical Microbiology and Hospital Hygiene, University of Marburg
- Felix Picard
- Institute for Medical Microbiology and Hospital Hygiene, University of Marburg
- Hartmann Raifer
- Institute for Medical Microbiology and Hospital Hygiene, University of Marburg
- Lucia Campos Carrascosa
- Institute for Medical Microbiology and Hospital Hygiene, University of Marburg
- Anna Guralnik
- Institute for Medical Microbiology and Hospital Hygiene, University of Marburg
- Yajuan Zhang
- Institute for Medical Microbiology and Hospital Hygiene, University of Marburg
- Matthias Klein
- Institute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz
- Stefan Bittner
- Department of Neurology at the University Medical Center of the Johannes Gutenberg-University Mainz
- Falk Steffen
- Department of Neurology at the University Medical Center of the Johannes Gutenberg-University Mainz
- Sonja Moos
- Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz
- Federico Marini
- Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg-University Mainz
- Renee Gloury
- The Peter Doherty Institute for Infection and Immunity, Dept. of Microbiology and Immunology, University of Melbourne
- Florian C. Kurschus
- Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz
- Ying-Yin Chao
- Center for Translational Cancer Research TranslaTUM, Technical University of Munich
- Wilhelm Bertrams
- Institute for Lung Research, Universities of Giessen and Marburg Lung Center, Philipps-University Marburg, Member of the German Center for Lung Research (DZL)
- Veronika Sexl
- Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna
- Bernd Schmeck
- Institute for Lung Research, Universities of Giessen and Marburg Lung Center, Philipps-University Marburg, Member of the German Center for Lung Research (DZL)
- Lynn Bonetti
- Dept. of Infection and Immunity, Experimental and Molecular Immunology, Luxembourg Institute of Health
- Melanie Grusdat
- Dept. of Infection and Immunity, Experimental and Molecular Immunology, Luxembourg Institute of Health
- Michael Lohoff
- Institute for Medical Microbiology and Hospital Hygiene, University of Marburg
- Christina E. Zielinski
- Center for Translational Cancer Research TranslaTUM, Technical University of Munich
- Frauke Zipp
- Department of Neurology at the University Medical Center of the Johannes Gutenberg-University Mainz
- Axel Kallies
- The Peter Doherty Institute for Infection and Immunity, Dept. of Microbiology and Immunology, University of Melbourne
- Dirk Brenner
- Dept. of Infection and Immunity, Experimental and Molecular Immunology, Luxembourg Institute of Health
- Michael Berger
- The Lautenberg Center for Immunology and Cancer Research, IMRIC, Faculty of Medicine, The Hebrew University
- Tobias Bopp
- Institute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz
- Björn Tackenberg
- Center of Neuroimmunology, Dept. of Neurology, University of Marburg
- Magdalena Huber
- Institute for Medical Microbiology and Hospital Hygiene, University of Marburg
- DOI
- https://doi.org/10.1038/s41467-019-13731-z
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 15
Abstract
Dimethyl fumarate (DMF) is a therapy for multiple sclerosis (MS) with undetermined mechanism of action. Here the authors find that clinical response to DMF associates with decrease in IL-17-producing CD8+ T cells (Tc17), delineate molecular pathways involved, and show that DMF suppresses Tc17 pathogenicity in a mouse model of MS.
